REG - ABCAM PLC - Result of General Meeting
11/11/2022 15:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221111:nRSK1970Ga&default-theme=true
RNS Number : 1970G ABCAM PLC 11 November 2022
ABCAM PLC
Result of General Meeting - Shareholders approve AIM Delisting
11 November 2022, Cambridge, UK - Abcam plc (AIM: ABC; Nasdaq: ABCM) ("Abcam"
or the "Company"), a global leader in the supply of life science research
tools, today announces that the resolution put to its General Meeting held
today for the cancellation of the admission of its Ordinary Shares to trading
on AIM was passed.
The votes were as follows:
Special Resolution In Favour % In Favour Against % Against % of ISC voted Withheld
1. Approve the cancellation of the admission to trading on AIM of the ordinary 189,580,480 98.19% 3,485,254 1.81% 84.29 60,213
shares of nominal value 0.2p each in the capital of the Company and authorise
the directors of the Company to take all action reasonable or necessary to
effect such cancellation
The issued share capital ("ISC") as of the date of the meeting was 229,059,401
Ordinary Shares.
The percentage of voting shares in favour and against is the percentage of
shares voted and exclude shares on which votes were withheld.
The Company will continue to provide shareholders with an opportunity to
deposit their Ordinary Shares with the Depositary in exchange for delivery of
ADSs, without cost, in connection with the AIM Delisting prior to or on 14
December 2022 (being the date on which the AIM Delisting takes effect).
Further details are set out in the Shareholder Circular dated 17 October 2022,
available at https://corporate.abcam.com/investors/aim-delisting/
(https://corporate.abcam.com/investors/aim-delisting/)
The Company confirms that, as at today's date, the pending timetable for the
cancellation of the admission to trading on AIM of the Company's ordinary
shares is as follows:
PENDING TIMETABLE
Last date for receipt by the Registrar from certificated shareholders of duly
completed Certificated Transfer Forms and original share certificates
5.00 p.m. on 1 December 2022
Latest date for receipt by the Depositary from CREST holders of duly completed
issuance forms
5.00 p.m. on 1 December 2022
Expected date for issuance of ADSs to block transfer participants 12 December 2022
Expected date of mailing of ADS confirmations to shareholders by the 13 December 2022
Depositary
Last day of dealings in the Ordinary Shares on AIM
13 December 2022
Cancellation of admission to trading on AIM of the Ordinary Shares
7.00 a.m. on 14 December 2022
_______
Notes to the timetable
(1) References to times and dates in this announcement are to times and
dates in London, United Kingdom, unless otherwise stated.
(2) Each of the times and dates in the above timetable are subject to
change. If any of the above times and/or dates change, the revised times
and/or dates will be notified to shareholders by announcement through a
Regulatory Information Service.
The capitalised terms used in this announcement have the meaning set out in
the announcement made by the Company at 7.00 a.m. on 17 October 2022.
For further information, please contact:
Abcam + 44 (0) 1223 696 000
Marc Perkins, Company Secretary +1 617 577 4205
Tommy J. Thomas, CPA, Vice President, Investor Relations
Numis - Nominated Advisor & Joint Corporate Broker + 44 (0) 20 7260 1000
Freddie Barnfield / Duncan Monteith
Morgan Stanley - Joint Corporate Broker + 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting + 44 (0) 20 3727 1000
Ben Atwell / Lydia Jenkins / Julia Bradshaw
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life
science researchers globally to achieve their mission faster. Providing the
research and clinical communities with tools and scientific support, the
Company offers highly validated antibodies, assays and other research tools to
address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's
ambition is to be the most influential company in life sciences by helping
advance global understanding of biology and causes of disease, which, in turn,
will drive new treatments and improved health.
Abcam's worldwide customer base of approximately 750,000 life science
researchers uses Abcam's antibodies, reagents, biomarkers and assays. By
actively listening to and collaborating with these researchers, the Company
continuously advances its portfolio to address their needs. A transparent
program of customer reviews and datasheets, combined with industry-leading
validation initiatives, gives researchers increased confidence in their
results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served
customers in more than 130 countries. Abcam's ordinary shares are listed on
the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs)
trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information, please visit www.abcam.com or www.abcamplc.com
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any express or implied
statements contained in this announcement that are not statements of
historical fact may be deemed to be forward-looking statements, including,
without limitation, statements regarding Abcam's portfolio and ambitions,
expectations surrounding the timing of the AIM Delisting, as well as
statements that include the words "expect," "intend," "plan," "believe,"
"project," "forecast," "estimate," "may," "should," "anticipate" and similar
statements of a future or forward-looking nature. Forward-looking statements
are neither promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially from those
projected, including, without limitation, the important factors discussed
under the caption "Risk Factors" in Abcam's Annual Report on Form 20-F for the
year ended 31 December 2021, which is on file with the SEC and is available on
the SEC website at www.sec.gov, as such factors may be updated from time to
time in Abcam's other filings with the SEC. Any forward-looking statements
contained in this announcement speak only as of the date hereof and
accordingly undue reliance should not be placed on such statements. Abcam
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this announcement, whether as a result
of new information, future events or otherwise, other than to the extent
required by applicable law.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMFLFESLFLLLIF